Sweden · Delayed Price · Currency is SEK OncoZenge AB Statistics
Total Valuation
OncoZenge AB has a market cap or net worth of SEK 72.59 million. The enterprise value is 71.30 million.
| Market Cap | 72.59M |
| Enterprise Value | 71.30M |
Important Dates
The last earnings date was Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoZenge AB has 12.65 million shares outstanding.
| Current Share Class | 12.65M |
| Shares Outstanding | 12.65M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 35.22% |
| Owned by Institutions (%) | 11.67% |
| Float | 5.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.75 |
| PB Ratio | 7.26 |
| P/TBV Ratio | 23.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.37 |
| EV / Sales | 26.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.80
| Current Ratio | 2.80 |
| Quick Ratio | 2.64 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,567.25 |
Financial Efficiency
Return on equity (ROE) is -47.77% and return on invested capital (ROIC) is -29.84%.
| Return on Equity (ROE) | -47.77% |
| Return on Assets (ROA) | -27.04% |
| Return on Invested Capital (ROIC) | -29.84% |
| Return on Capital Employed (ROCE) | -62.73% |
| Revenue Per Employee | 2.71M |
| Profits Per Employee | -6.27M |
| Employee Count | 1 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.65% in the last 52 weeks. The beta is 1.44, so OncoZenge AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | +38.65% |
| 50-Day Moving Average | 6.28 |
| 200-Day Moving Average | 5.91 |
| Relative Strength Index (RSI) | 41.63 |
| Average Volume (20 Days) | 61,373 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OncoZenge AB had revenue of SEK 2.71 million and -6.27 million in losses. Loss per share was -0.54.
| Revenue | 2.71M |
| Gross Profit | 2.71M |
| Operating Income | -6.27M |
| Pretax Income | -6.27M |
| Net Income | -6.27M |
| EBITDA | n/a |
| EBIT | -6.27M |
| Loss Per Share | -0.54 |
Balance Sheet
The company has 1.29 million in cash and n/a in debt, giving a net cash position of 1.29 million or 0.10 per share.
| Cash & Cash Equivalents | 1.29M |
| Total Debt | n/a |
| Net Cash | 1.29M |
| Net Cash Per Share | 0.10 |
| Equity (Book Value) | 9.99M |
| Book Value Per Share | 0.85 |
| Working Capital | 3.14M |
Cash Flow
| Operating Cash Flow | -8.37M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -230.99% and -231.10%.
| Gross Margin | 100.00% |
| Operating Margin | -230.99% |
| Pretax Margin | -231.10% |
| Profit Margin | -231.10% |
| EBITDA Margin | n/a |
| EBIT Margin | -230.99% |
| FCF Margin | n/a |
Dividends & Yields
OncoZenge AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -8.64% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OncoZenge AB has an Altman Z-Score of 11.24.
| Altman Z-Score | 11.24 |
| Piotroski F-Score | n/a |